ReviewNeuroscience bulletin2021
Illuminating Neural Circuits in Alzheimer's Disease.
Review in Neuroscience bulletin, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Large-Scale Neural Recording Technologies for Investigating Circuit Dysfunction and Functional Biomarker Discovery in Animal Models of Alzheimer's Disease.International journal of molecular sciences · 2026Review
- The medial septum-hippocampus-lateral septum circuitry in spatial memory: linking healthy function to early Alzheimer's disease and translational opportunities.Translational neurodegeneration · 2025Review
- RSV Infection and Neurodegenerative Diseases: A Hypothesis of Energy Metabolism Disruption via the Lung-Brain Axis.Aging and disease · 2025Review
- Electroacupuncture Alleviates Memory Deficits in APP/PS1 Mice by Targeting Serotonergic Neurons in Dorsal Raphe Nucleus.Current medical science · 2024Article
- Updates in Alzheimer's disease: from basic research to diagnosis and therapies.Translational neurodegeneration · 2024Review
- Myosin Va-dependent Transport of NMDA Receptors in Hippocampal Neurons.Neuroscience bulletin · 2024Article
- Multimodal Nature of the Single-cell Primate Brain Atlas: Morphology, Transcriptome, Electrophysiology, and Connectivity.Neuroscience bulletin · 2024Review
- Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer's disease.Molecular psychiatry · 2024Review
- Review
- Enhancement of neural regeneration as a therapeutic strategy for Alzheimer's disease (Review).Experimental and therapeutic medicine · 2023Review
- One Small Step for Neurotechnology, One Giant Leap for an In-Depth Understanding of the Brain.Neuroscience bulletin · 2023Article
- Disrupted Maturation of Prefrontal Layer 5 Neuronal Circuits in an Alzheimer's Mouse Model of Amyloid Deposition.Neuroscience bulletin · 2023Article
- Secreted endogenous macrosomes reduce Aβ burden and ameliorate Alzheimer's disease.Science advances · 2023Article
- Release of Endogenous Brain-derived Neurotrophic Factor into the Lateral Entorhinal Cortex from the Paraventricular Thalamus Ameliorates Social Memory Deficits in a Mouse Model of Alzheimer's Disease.Neuroscience bulletin · 2022Article
- Neuroprotective Mechanisms of Puerarin in Central Nervous System Diseases: Update.Aging and disease · 2022Article
- Proteomic analysis of human hippocampal subfields provides new insights into the pathogenesis of Alzheimer's disease and the role of glial cells.Brain pathology (Zurich, Switzerland) · 2022Article
- Review
- Optogenetics: implications for Alzheimer's disease research and therapy.Molecular brain · 2022Review
- Post-Ischemic Neurodegeneration of the Hippocampus Resembling Alzheimer's Disease Proteinopathy.International journal of molecular sciences · 2021Review
- Influence of the anatomical features of different brain regions on the spatial localization of fiber photometry signals.Biomedical optics express · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder and there is currently no cure. Neural circuit dysfunction is the fundamental mechanism underlying the learning and memory deficits in patients with AD. Therefore, it is important to understand the structural features and mechanisms underlying the deregulated circuits during AD progression, by which new tools for intervention can be developed. Here, we briefly summarize the most recently established cutting-edge experimental approaches and key techniques that enable neural circuit tracing and manipulation of their activity. We also discuss the advantages and limitations of these approaches. Finally, we review the applications of these techniques in the discovery of circuit mechanisms underlying β-amyloid and tau pathologies during AD progression, and as well as the strategies for targeted AD treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.